PUBLISHER: DelveInsight | PRODUCT CODE: 1462267
PUBLISHER: DelveInsight | PRODUCT CODE: 1462267
"P2B-001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about P2B-001 for Parkinson's disease in the seven major markets. A detailed picture of the P2B-001 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the P2B-001 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the P2B-001 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
P2B-001 being developed by Pharma Two B, is a novel, once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose Monoamine Oxidase-B (MAO-B) inhibitor, developed specifically for the treatment of Parkinson's disease.
The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each drug. Lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs in an improved formulation that is hoped to be more effective in controlling Parkinson's disease symptoms and with fewer side effects than each of the drugs taken alone or the currently available commercial drugs taken together.
Pharma Two B has completed Phase IIb and Phase III studies investigating P2B001's efficacy and safety as a once-daily, no-titration treatment for early-stage Parkinson's disease. An NDA submission to the FDA is being prepared. In a previously completed clinical trial, a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with a placebo.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
P2B-001 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of P2B-001 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of P2B-001 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.